Self-limited focal epilepsy and childhood apraxia of speech with WAC pathogenic variants


• Four children with heterozygous WAC pathogenic variants and epilepsy are described.

• All children had global developmental impairment with language most severely affected.

• Two children had childhood apraxia of speech and 2 had autism spectrum disorder.

• Seizures were self-limited in 2, and controlled on monotherapy in the other 2.

• Seizures were typically focal from sleep; onset age ranged from 6 months to 14 years.


Heterozygous pathogenic WAC variants cause Desanto-Shinawi syndrome; affected patients have dysmorphic features, developmental impairment and behavioral abnormalities. Seizures are reported in one quarter, including tonic-clonic, absence, and febrile seizures. This study aimed to better understand the phenotypic spectrum of epilepsy and development in Desanto-Shinawi syndrome. We identified four children with seizures and pathogenic WAC variants, including two siblings. All had global developmental impairment with language affected most severely; two had diagnoses of childhood apraxia of speech and two had autism spectrum disorder. Seizure onset age ranged from six months to 14 years. Seizures always occurred from sleep and were focal impaired awareness with motor features in three patients, with one having bilateral tonic-clonic seizures of suspected focal onset. Two patients had spontaneous seizure resolution without treatment, and the remaining two were well-controlled on monotherapy. EEG was normal in two patients; one had focal right frontal spikes in drowsiness and sleep while the last had independent centrotemporal spikes from both hemispheres, activated in sleep. All patients had heterozygous truncating pathogenic WAC variants, with negative parental testing. The findings in this cohort of patients suggest that epilepsy in Desanto-Shinawi syndrome is usually focal and self-limited, and may fall within the epilepsy-aphasia spectrum.

Click here for more details

Related Post

  • Posted on 24 October, 2023
    Friedreich ataxia (FA) is an inherited, multisystem neurodegenerative disease that results in profound changes to speech, swallowing, balance, walking, cardiac...
    • Posted on 30 March, 2023
      L16HTHOUSE is a research trial testing an experimental medication for treating speech, motor, learning, and other developmental delays in children...
      • Posted on 30 March, 2023
        Ataxia telangiectasia (A-T) is a rare inherited condition that affects the nervous and immune systems. A-T typically impacts movement, vision...